Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action. - Wikidata - wikimedia - TriplyDB

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

http://www.wikidata.org/entity/Q37650120

about

Redefining the viral reservoirs that prevent HIV-1 eradication Concentrations of Pro-Inflammatory Cytokines Are Not Associated with Senescence Marker p16INK4a or Predictive of Intracellular Emtricitabine/Tenofovir Metabolite and Endogenous Nucleotide Exposures in Adults with HIV Infection In vitro HIV-1 evolution in response to triple reverse transcriptase inhibitors & in silico phenotypic analysis Humanized mice recapitulate key features of HIV-1 infection: a novel concept using long-acting anti-retroviral drugs for treating HIV-1 Genetic characterization and antiretroviral resistance mutations among treatment-naive HIV-infected individuals in Jiaxing, China.Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy.Pharmacological considerations for tenofovir and emtricitabine to prevent HIV infection HIV protease inhibitors do not cause the accumulation of prelamin A in PBMCs from patients receiving first line therapy: the ANRS EP45 "aging" study Intracellular drug concentrations.HIV protease inhibitors and obesity Very high concentrations of active intracellular phosphorylated emtricitabine in neonates (ANRS 12109 trial, step 2).Evaluation of the mean corpuscular volume of peripheral blood mononuclear cells of HIV patients by a coulter counter to determine intracellular drug concentrations.Joint population pharmacokinetic analysis of zidovudine, lamivudine, and their active intracellular metabolites in HIV patients Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted.Alterations in cellular pharmacokinetics and pharmacodynamics of elvitegravir in response to ethanol exposure in HIV-1 infected monocytic (U1) cells.Validation and Application of a Liquid Chromatography-Tandem Mass Spectrometry Method To Determine the Concentrations of Sofosbuvir Anabolites in Cells.Association of lopinavir concentrations with plasma lipid or glucose concentrations in HIV-infected South Africans: a cross sectional study.Plasma and intracellular pharmacokinetics of darunavir/ritonavir once daily and raltegravir once and twice daily in HIV-infected individuals.Nevirapine inhibits the anti-HIV activity of CD8+ cells Antiretroviral drug transporters and metabolic enzymes in human testicular tissue: potential contribution to HIV-1 sanctuary site.Influence of drug transport proteins on the pharmacokinetics and drug interactions of HIV protease inhibitors.Multiscale Systems-Pharmacology Pipeline to Assess the Prophylactic Efficacy of NRTIs Against HIV-1.Effects of political conflict-induced treatment interruptions on HIV drug resistance Interactions between tenofovir and nevirapine in CD4+ T cells and monocyte-derived macrophages restrict their intracellular accumulation.Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect.Effects of substitutions at the 4' and 2 positions on the bioactivity of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.BMS-986001, an HIV nucleoside reverse transcriptase inhibitor, does not degrade mitochondrial DNA in long-term primary cultures of cells isolated from human kidney, muscle, and adipose tissue.Favipiravir Pharmacokinetics in Nonhuman Primates and Insights for Future Efficacy Studies of Hemorrhagic Fever Viruses.Tissue penetration of antifungal agents.Antiretroviral drugs induce oxidative stress and neuronal damage in the central nervous system Virological efficacy of 24-week fozivudine-based regimen in ART-naive patients from Tanzania and Côte d'Ivoire.Spatial modeling of HIV cryptic viremia and 2-LTR formation during raltegravir intensification.Nucleoside reverse transcriptase inhibitor toxicity and mitochondrial DNA.Clinical pharmacology profile of raltegravir, an HIV-1 integrase strand transfer inhibitor.The role of cytokines in the regulation of drug disposition: extended functional pleiotropism?Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.Potential effect of pharmacogenetics on maternal, fetal and infant antiretroviral drug exposure during pregnancy and breastfeeding.Inflammation and pharmacokinetics: potential implications for HIV-infection.Pharmacogenetic considerations in the treatment of HIV.Therapeutic drug monitoring of antiretroviral drugs in HIV-infected patients.

P2860

Q26827255-6E1C03A5-34F1-4D94-9EBF-2842533D6656 Q28468505-D7CBB4AF-79C7-4E36-B780-A1872AF1C519 Q28486262-D0EE0A50-62A1-41F3-81B5-24636F3C1954 Q28728527-2096F7F5-ABB8-4520-8761-4D1775CB0A7C Q33566910-C473D7F2-3C83-472F-A71D-5932CC33EF38 Q34178412-4D61BFF0-FDA0-4140-9E7D-CF2655752E5F Q34481359-43FB52A8-B8A7-4666-8848-31BCFDA07C77 Q34534986-79726081-0F4A-40D0-A36E-0E94F2F814D9 Q34567127-BE0E928D-6F07-4794-91DA-F043A26FD318 Q34792983-2FA4AF09-E195-4619-951B-20430C251683 Q35004837-9672E0D5-9426-4CBD-A9D6-8F5990FE7020 Q35005018-026E21F0-7055-40AD-AEA5-3C0570697845 Q35065817-69E2450D-5CF4-4E72-8327-E0D6C8B0EA70 Q36288297-5BC98C49-E154-449F-9178-A48D0170A828 Q36288425-2311E184-05DC-499D-A0BC-2388DAA9EA15 Q36290604-B61BE5B6-41D1-4A60-9AFB-8C97B5F56C8F Q36498717-C2014392-D49C-47CF-81F7-8F52CE00CD54 Q36675900-236C309B-3320-462B-A49B-5F3A52D543B5 Q36843910-63BFCBBA-E5E8-4830-B962-86FE9B0C4873 Q36977376-B9C5D2F9-DA92-4718-A8AA-3AAFEC38C6D9 Q37113947-D0EAA36F-D7D3-456D-B7D9-19682D055EA1 Q37126494-6A6343B8-25D0-4EA9-A170-5AA9391A15E8 Q37175897-4BD6D0AD-5360-48E2-BF07-61E98E687F48 Q37232200-5FF9D181-60CC-4A3E-B3FF-503035941BA9 Q37258762-01824B7E-EF04-40F8-BA4E-57D29D846313 Q37335626-709C3292-8C2B-42DC-9697-76DF4558E306 Q37335637-DDAA68C1-E6B0-4C3F-8EBE-2686F8F6FFFD Q37538706-341B52BF-3B72-43BF-AADD-CC0CDF295086 Q37544911-259B4D51-E93C-4860-A6B1-3BB5FE085623 Q37592018-217239F9-A143-44F1-BB33-7A5E4C32BF73 Q37613239-585D52F2-7110-4598-B8BE-423956D279E8 Q37621893-0C33D5C7-5BA0-4591-B544-9A984CD2AABC Q37798546-381973D3-B8E3-49E9-95FC-0CBFBA233EDF Q37826300-6DCC3695-3930-449F-B184-94928307366E Q37836908-B8F16FB8-7D4E-46EA-B6FC-1949FED5C834 Q37866289-9F4B02DA-F779-49AE-A64B-3C900109B79D Q38051400-F72071E6-93F4-40C0-A975-CC5CB229366D Q38740792-58BF028C-95CB-442B-9549-4924BFCAFCC1 Q38782609-B27282C7-7742-47FF-9410-E00C55D4667A Q38954109-7E0C3641-CC2B-4DD7-9ECC-F06EDF140CE7

P2860

Intracellular Pharmacokinetics of Antiretroviral Drugs in HIV-Infected Patients, and their Correlation with Drug Action.

http://www.wikidata.org/entity/Q37650120

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on January 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Intracellular Pharmacokinetics ...... Correlation with Drug Action.

@en

Intracellular Pharmacokinetics ...... Correlation with Drug Action.

@nl

type

label

Intracellular Pharmacokinetics ...... Correlation with Drug Action.

@en

Intracellular Pharmacokinetics ...... Correlation with Drug Action.

@nl

prefLabel

Intracellular Pharmacokinetics ...... Correlation with Drug Action.

@en

Intracellular Pharmacokinetics ...... Correlation with Drug Action.

@nl

P1433

Q37650120-465C5C34-67A6-4CD1-B469-BC1756D74ACC

P1476

Q37650120-58613596-790F-4456-8149-07E69CA0F50D

P2093

Q37650120-35831CCE-CA59-4E7A-B957-6FD92DBB46A0

Q37650120-3E0737CE-3D62-4CD2-9B56-F532AD370B5E

Q37650120-724BA5A2-412D-4F22-9768-C305C07E3C82

Q37650120-8BD5A2C8-4AF2-4EAA-8D1A-400DF6C08AD7

Q37650120-C0A15BB5-9904-45F5-8E09-C667921EABE6

Q37650120-FD6D7CB4-C374-4D39-85DC-C80E86F5AA4A

P2860

Q37650120-40B43E13-040F-415E-BD1B-97972D1EBC38

Q37650120-864744F9-F46D-4437-9307-7790B97ED160

Q37650120-99072E9D-8A74-4CBE-A63F-DE6B7ED34724

Q37650120-A799C854-38EF-4A7C-B534-143C233C19DB

Q37650120-A8B21898-A3AF-4B08-870B-A155BF536E8C

Q37650120-FF17F90F-5F66-44AF-8939-C98AD68E8322

P2888

Q37650120-6225E437-9E07-42C0-9212-F9FC937C2E7B

P304

Q37650120-EF4E31E2-7B34-4D4F-8839-898129221CF8

P31

Q37650120-02B3162D-7FDA-4DD7-BB8B-A4E61899BEA7

P356

Q37650120-898BD84E-4828-4FE1-8639-4C19E703E18C

P433

Q37650120-81E8A932-6DF5-4B1A-93DB-2F1BC99074B0

P478

Q37650120-428908AE-2188-4ABB-ADA8-5C7390B22B32

P577

Q37650120-56B1A48B-B6EB-412C-AA42-C7A21AF6F6B0

P5875

Q37650120-4A6B14FF-2432-43E8-9E47-ED0D247295B8

P698

Q37650120-4E30D1D2-C859-4224-BF1F-36C1E79973B1

P921

Q37650120-C32466D3-9840-4455-A480-C4A429B9612A

Q37650120-F4144782-AF88-4168-A34E-78D82AD50CD4

Q37650120-FE93B62F-8FCB-4F03-BE85-E9F4EAA433A4

P356

11318110-000000000-00000

P1433

Clinical Pharmacokinetics

P1476

Intracellular Pharmacokinetics ...... Correlation with Drug Action.

@en

P2093

Anne-Marie Taburet

http://www.w3.org/2001/XMLSchema#string

Caroline Bazzoli

http://www.w3.org/2001/XMLSchema#string

Clotilde Le Tiec

http://www.w3.org/2001/XMLSchema#string

Elisabeth Rey

http://www.w3.org/2001/XMLSchema#string

France Mentré

http://www.w3.org/2001/XMLSchema#string

Vincent Jullien

http://www.w3.org/2001/XMLSchema#string

P2860

Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virus.

Intracellular pharmacology of nucleoside analogues and protease inhibitors: role of transporter molecules.

Efficacy and tolerability of stavudine plus lamivudine in treatment-naive and treatment-experienced patients with HIV-1 infection.

Nucleoside reverse transcriptase inhibitor usage and the incidence of peripheral neuropathy in HIV/AIDS patients.

Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals.

Risk of side effects associated with the use of nevirapine in treatment-naïve patients, with respect to gender and CD4 cell count.

P2888

11318110-000000000-00000

P304

17-45

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/11318110-000000000-00000

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

40678870

http://www.w3.org/2001/XMLSchema#string

P698

20000887

http://www.w3.org/2001/XMLSchema#string

P921

antiretroviral drug